Our Prescription Drugs division is conducted through two joint ventures in which we nominate management and run the day-to-day operations:
Our Prescription Drugs business employs a physician-targeted marketing model that is focused on promoting its products by providing physicians and hospitals with information on the benefits and differentiating clinical aspects of our products, building an extensive prescription drug sales and distribution network across China.
Manufacturing, marketing and distributing proprietary and licensed prescription drugs.
Shanghai Hutchison Pharmaceuticals primarily engages in the manufacture and sale of prescription drug products originally contributed by our joint venture partner, as well as third-party prescription drugs with a focus on cardiovascular medicine. Its proprietary products are sold under the "Shang Yao" brand, literally meaning "Shanghai pharmaceuticals," a trademark that has been used for over 40 years in the pharmaceutical retail market, primarily in Eastern China.
Shanghai Hutchison Pharmaceuticals sells its products and its third-party licensed prescription drugs directly to distributors, and also markets and sells third-party prescription drugs in collaboration with Hutchison Sinopharm.
Its medical sales representatives promote its products to doctors and purchasing managers in hospitals, clinics and pharmacies as part of its marketing efforts.
Shanghai Hutchison Pharmaceuticals has approximately 2,400 medical sales representatives and about 550 manufacturing employees across China.
Providing logistics services and marketing and distribution for prescription drugs manufactured by third parties.
In April 2014, we commenced operating Hutchison Sinopharm, a Shanghai-based Good Supply Practice-certified company focused on providing logistics services to, and distributing and marketing prescription drugs manufactured by, third-party pharmaceutical companies in China.
We intend to expand Hutchison Sinopharm to operate as a full-service, third-party prescription drug commercialization company in China. In the longer term, our marketing network's ability to adapt to effectively market new drugs will help us launch any new oncology or immunology drugs developed by our Innovation Platform.
Hutchison Sinopharm has entered into agreements with multinational and Chinese pharmaceutical manufacturers to market and distribute eight prescription products in China. The two primary products are Seroquel®, AstraZeneca's first-line antipsychotic medicine for the treatment of schizophrenia and bipolar disorder; and Concor®, Merck Serono's beta-blocker for various cardiovascular diseases.
We also continue to operate Hutchison Sinopharm’s legacy business, which is focused on providing Shanghai logistics and distribution services to third-party pharmaceutical companies.